The use of intravitreal/periocular therapies in patients with uveitis during the COVID-19 pandemic
| Number of eyes receiving local therapies | 22 | |||
|---|---|---|---|---|
| Number of eyes receiving local therapies due to disease reactivation related to reduced systemic therapy | 7 | |||
| Agent | Number of eyes receiving treatment* | Indications | Number of eyes receiving treatment | Number of eyes with relapse due to changed systemic therapy† |
| Dex implant | 10 | Active choroiditis | 1 | 1 |
| VKH disease | 2 | 2 | ||
| Macular oedema | 4 | 0 | ||
| Retinal vasculitis | 2 | 2 | ||
| Intermediate uveitis | 1 | 1 | ||
| Triamcinolone (periocular) | 6 | Macular oedema and active vasculitis | 6 | 0 |
| Triamcinolone (intravitreal) | 2 | Active vasculitis | 2 | 1 |
| Ranibizumab | 4 | Macular oedema | 4 | – |
*Each eye received a single injection of the pharmacological agent.
†Indicates the number of eyes that received intravitreal/periocular therapies due to disease reactivation which was related to reduction in doses of systemic corticosteroids or immunomodulatory therapy.
Dex, Dexamethasone; VKH, Vogt-Koyanagi-Harada’s disease.